Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B

Cited by (325)

Items 301–325 of 325

1. Az antifungális rezisztencia kialakulásának és következményének vizsgálata a humánpatogén Candida auris esetében
   Flóra Bohner · 2024
2. The Role of Drug Resistance in Candida Inflammation and Fitness
   Gabriella Piatti, Alberto Vitale, Anna Maria Schito, Susanna Penco, Danièle Saverino · 2025 · Microorganisms
3. Ergosterol-depleted clinical isolates of Nakaseomyces glabratus can develop multi-drug resistance without apparent fitness and virulence defects
   Alexander Maximilian Aldejohann, Nadja Thielemann, Aina Zurita Martinez, Christoph Müller, Tom Gräfenhan, Richard Kriz, Heimo Lagler, Isabell S. Behr, Nathalie Reus, Annika Schöninger et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
4. Exploring alternative therapeutic strategies against drug-resistant Candida albicans for immunocompromised patients
   Swarupa Ghosh, Suranjana Sarkar, Pramita Garai, Arpan Kumar Maiti, Nimai Chandra Saha, Priyajit Banerjee · 2025 · Discover Applied Sciences
5. Anti-psychotic drugs act synergistically in combination with antifungal drugs to inhibit drug-resistant Cryptococcus and Candida species
   Magali Ayala, Alifia Jakamartana, Rodrigo Mamede Dos Santos Costa, Joseph M. Bednarek, Christian T. Moreau, C. K. Cheung, Jessica C. S. Brown · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
6. Étude du stress oxydant durant la phagocytose de la levure pathogène émergente Candida glabrata
   Leïla Bouchab · 2016
7. Développement de nanovecteurs innovants destinés au traitement de la leishmaniose viscérale.
   Kevin Matha · 2020 · theses.fr (ABES)
8. Genome scale analysis of Arabidopsis thaliana quantitative disease resistance to the generalist fungal pathogen Sclerotinia sclerotiorum
   Thomas Badet · 2017
9. Agricultural azole fungicides induce cross-resistance to medical antifungals in Candida tropicalis : a One Health perspective on antifungal resistance
   Shuaihu Li, Tianren Hu, CB Li, Tianchen Tan, Haiqing Chu, Guanghua Huang · 2026 · Mycology&#58 An International Journal on Fungal Biology
10. Emerging Antifungal Resistance in Ocular Infections
    Haroldo César de Oliveira, Aileen Miwa Tabuse, Ana Luísa Höfling-Lima, Anderson Messias Rodrigues · 2026 · Springer eBooks
11. Urosepsis by multidrug-resistant Nakaseomyces glabratus with non-functional Erg3 and Erg11—do collateral sensitivity and a unique mode of action make nitroxoline a viable UTI antifungal?
    Hans Carolus, Vladislav V. Biriukov, Jolien Vreys, Celia Lobo Romero, Juan Paulo Herrera Ávila, Rudy Vergauwen, Dimitrios Sofras, Jana Viktoria Nysten, Giel Vanreppelen, Lore Vinken et al. · 2026 · mBio
12. Ergosterol-depleted clinical isolates of Nakaseomyces glabratus can develop multi-drug resistance without severe fitness defects or attenuated virulence in an invertebrate infection model
    Alexander Maximilian Aldejohann, Nadja Thielemann, Aina Zurita Martinez, Christoph Müller, Tom Gräfenhan, Richard Kriz, Heimo Lagler, Isabell S. Behr, Nathalie Reus, Annika Schöninger et al. · 2026 · mBio
13. Antifungal Chalcones
    Patrick Rômbola Ozanique, João Gabriel Giaretta Avesani, Luís Octávio Regasini · 2026 · Springer eBooks
14. Dynamics associated with the efflux pumps in biofilms and persister cells of Cryptococcus neoformans and Cryptococcus gattii
    Gabriel Rezende Pimenta, Marcos William de Lima Gualque, Maria Júlia Siqueto, Samanta de Matos Silva, Luís Octávio Regasini, Maria José Soares Mendes‐Giannini, Ana Marisa Fusco‐Almeida · 2026 · Microbiology Spectrum
15. Antimicrobial Peptides as Eco-Innovative Therapeutics to Overcome Antifungal Pressure-Induced Resistance in Candida Infections
    Bahgat Fayed · 2026 · Current Microbiology
16. The common evolution of fungicide persistence in cryptococcosis patients
    Yuyan Xie, Weixin Ke, Xin Fan, Heping Xu, Wenzhao Wang, Zhen Zeng, Na Zhang, Haoran Ma, Zhongjie Tang, Huawei Zhu et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
17. Anti-psychotic drugs act synergistically in combination with antifungal drugs to inhibit drug-resistant Cryptococcus neoformans and Candida albicans
    Magali Ayala, Alifia Jakamartana, Rodrigo Mamede Dos Santos Costa, Eric Cheuk-Kiu Cheung, Joseph M. Bednarek, Christian T. Moreau, Jessica C. S. Brown · 2026 · mSphere
18. Antifungal drug resistance in Candida auris: molecular mechanisms and emerging therapeutic approaches
    Trinh Phan-Canh, Adelheid Elbe‐Bürger, Karl Kuchler · 2026 · Trends in Microbiology
19. Predicting resistance evolution to guide antibiotic development
    Csaba Pál, Petra Éva Szili, Szilvia Juhász · 2026 · Nature Reviews Microbiology
20. Established determinants of replicative lifespan, including mitochondrial DNA, play a limited role in early yeast stress-resistance decline
    Aglaia V. Azbarova, Kseniia V. Galkina, Дмитрий Алексеевич Кнорре · 2026 · Biogerontology
21. BindingDB Entry 50007885: Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
    BindingDB · 2021 · UC San Diego
22. BindingDB Entry 7376: A Fungal-Selective Cytochrome bc1 Inhibitor Impairs Virulence and Prevents the Evolution of Drug Resistance.
    BindingDB · 2016 · UC San Diego
23. BindingDB Entry 50023176: Is a Fungal Apocalypse Inevitable or Just a Hallucination? An Overview of the Antifungal Armamentarium Used in the Fight against Pathogenic Fungi.
    BindingDB · 2026 · UC San Diego
24. BindingDB Entry 50002345: Emerging New Targets for the Treatment of Resistant Fungal Infections.
    BindingDB · 2020 · UC San Diego
25. Extracellular vesicle packaging of a supercluster-encoded antimicrobial combination with enhanced potency against fungal biofilms
    Kirsten J. Meyer, Valerie Chow, Elaina Piliouras, Yunjin Lee, Hanna Ostapska, Oliver Ojeda Valencia, Ines Ben Makhlouf, Nicole Robbins, Leah E. Cowen, Justin Rea Nodwell · 2026 · bioRxiv (Cold Spring Harbor Laboratory)